New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
09:14 EDTMPEL, WYNN, LVS, MGM, ELN, BIIB, VMED, ZNGA, TWX, GDP, RS, RL, DIS, LBTYA, MUSA, SFLYOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Disney (DIS), up 2.8%... Time Warner (TWX), up 2.7%... Shutterfly (SFLY), up 16.9%... Zynga (ZNGA), up 5.5%... Ralph Lauren (RL), up 4.9%... ALSO HIGHER: Goodrich Petroleum (GDP), up 12.1% after announcing well results... Biogen (BIIB), up 5% after deal to pay $3.25B to acquire full rights and control of Tysabri from Elan (ELN)... DOWN AFTER EARNINGS: C.H. Robinson (CHRW), down 7.1%... Suncor (SU), down 3.7%... Hain Celestial (HAIN), down 2.7%... ALSO LOWER: Las Vegas Sands (LVS), down 2%, Melco Crown (MPEL), down 3.2%, MGM Resorts (MGM), down 1.3%, and Wynn Resorts (WYNN), down 3.4%, after The Times of London said China's government will begin clamping down on Macau junket operators... ACQUISITIONS MOVERS: Metals USA (MUSA), up 12.8%, to be acquired by Reliance Steel (RS) for $20.65 per share... Virgin Media (VMED), down 1.5%, to be acquired by Liberty Global (LBTYA) in cash and stock deal valued at $23.3B.
News For DIS;TWX;SFLY;RL;ZNGA;MUSA;RS;VMED;LBTYA;GDP;BIIB;ELN;LVS;MPEL;MGM;WYNN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 19, 2015
17:46 EDTBIIBApplied Genetic says Biogen collaboration effective, equity investment closed
Subscribe for More Information
17:33 EDTGDPGoodrich Petroleum CFO Jan Schott to resign
Subscribe for More Information
06:14 EDTTWXIntel to launch contest show on Turner Broadcasting, WSJ reports
Intel (INTC) is making a foray into reality television by developing a contest show with Mark Burnett and Time Warner's (TWX) Turner Broadcasting unit, the Wall Street Journal reports. The program will be called "America's Greatest Makers" and will engage "do-it-yourselfers" who turn microchips and other components into devices and gadgets, competing for a $1M prize, the report says. The show is scheduled to appear on TV and other media channels in 2016, the report adds. Reference Link
August 18, 2015
16:49 EDTDISOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
16:00 EDTDISOptions Update; August 18, 2015
Subscribe for More Information
11:07 EDTDISDisney has a potential bearish pattern near the trigger point
There is a potential bearish pennant that is developing on the daily chart. A move below $106.50 would confirm that the pattern is active. Downside potential would be to the $92 to $91 area, if the pattern became active and completed. A sustained move above the pattern top at $109 or higher would void the pattern through time and price.
10:17 EDTDISDisney downgraded as Wells moves away from content providers
Subscribe for More Information
10:00 EDTDISOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:21 EDTBIIBBiogen long-term outlook still positive, says RBC Capital
Subscribe for More Information
07:13 EDTWYNN, MGM, LVS, MPELMacau GGR poised to sink 37% in August, says Bernstein
Subscribe for More Information
07:12 EDTDIS, TWXDisney downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded Disney (DIS) to Market Perform with a $112-$119 price target range saying value is shifting from content to distribution. Wells also downgraded CBS (CBS) and 21st Century Fox (FOXA) this morning to Market Perform while cutting its Diversified Media sector view to Market Weight. Time Warner (TWX) remains its only Outperform-rated media stock. Shares of Disney closed yesterday up $1.88 to $109.05.
07:05 EDTBIIBBiogen, ALS Association, Columbia collaborate to drive understanding of ALS
Biogen, the ALS Association and Columbia University Medical Center announced a new collaboration to better understand the differences and commonalities in the ALS disease process and how genes influence the clinical features of the disease. The project, "Genomic Translation for ALS Clinical care", will involve a combination of next generation genetic sequencing and detailed clinical phenotyping in 1500 people with ALS. The goal of the project is to provide a basis for the development of precision medicine, or more individually tailored therapies for ALS. "We want to bring genomics right to the point of care in ALS where instead of focusing on retrospective DNA samples with limited clinical information, we focus on patients who are under active clinical management," said ALS Association Chief Scientist Lucie Bruijn, Ph.D., M.B.A. "By focusing on patients seen by participating ALS clinics, this project will allow investigators to ask how different genetic causes of ALS translate into different clinical consequences."
August 17, 2015
20:09 EDTLBTYACable companies test virtual reality offerings, Variety says
Subscribe for More Information
16:53 EDTDISOn The Fly: Top stock stories for Monday
Subscribe for More Information
11:49 EDTTWXTime Warner price target lowered to $92 from $103 at Barrington
Barrington analyst James Goss lowered his price target for Time Warner to $92 to reflect more conservative multiple assumptions but keeps an Outperform rating on the name.
07:59 EDTDISDisney plans for Star Wars should ease investor concern, says FBR Capital
Subscribe for More Information
07:46 EDTGDPEnerCom to hold a conference
Subscribe for More Information
07:03 EDTBIIBBiogen: Clinical data supports long-term safety, efficacy of Alprolix
New clinical data support the long-term safety and efficacy of ALPROLIX in people with severe hemophilia B treated for up to two years, Biogen announced. Participants in the Phase 3, open-label extension study, B-YOND, maintained low bleeding rates with one to two week prophylaxis regimens, according to data from an interim analysis. Investigators presented these interim results for the first time at the 67th Annual Meeting for the National Hemophilia Foundation in Dallas. B-YOND is a multi-year study for people with severe hemophilia B who completed the Phase 3 pivotal B-LONG or Kids B-LONG studies. In this interim analysis, the median time on ALPROLIX during B-YOND was 27.6 months for adults and adolescents, and 47.7 weeks for children under age 12. The study's primary endpoint is inhibitor development, and no inhibitors have been reported to-date. There were three prophylactic dosing options for adult, adolescent, and pediatric participants in the B-YOND trial - weekly, individualized, and modified prophylaxis. An episodic treatment arm was also available for adult and adolescent patients.
August 16, 2015
16:59 EDTTWX'Straight Outta Compton' sidesteps rivals in $56.1M weekend debut
Subscribe for More Information
14:41 EDTDISDisney announces 'Star Wars' theme park expansion
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use